Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 4, 2008 - Issue 4
Submit an article Journal homepage
83
Views
21
CrossRef citations to date
0
Altmetric
Original Research

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

Walter Deberdt1 Eli Lilly Benelux, Eli Lilly and Company, Brussels, BelgiumCorrespondence[email protected]
,
Ilya Lipkovich2 Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
,
Alexandra N Heinloth3 i3Statprobe, Ingenix, Cary, NC, USA
,
Lin Liu2 Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
,
Sara Kollack-Walker2 Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
,
Sara E Edwards2 Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
,
Vicki Poole Hoffmann2 Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
&
Thomas A Hardy2 Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
 show all
Pages 713-720 | Published online: 08 Aug 2008

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.